Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer

Published:2020-05 Issue: Volume:130 Page:219-227
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Kim Richard D.,McDonough Shannon,El-Khoueiry Anthony B.,Bekaii-Saab Tanios S.,Stein Stacey M.,Sahai Vaibhav^ORCID,Keogh George P.,Kim Edward J.^ORCID,Baron Ari D.^ORCID,Siegel Abby B.,Barzi Afsaneh,Guthrie Katherine A.^ORCID,Javle Milind,Hochster Howard

Funder

National Institutes of Health

National Cancer Institute

Bayer

BMS

Eisai

Astra Zeneca

Astex

Celgenem BMS

Halozyme

Medimmune

Sanumed

Boston Biomedical

Merck

Celegene

Oncomed

EpicentRx

Astellas Pharma

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference31 articles.

1. Cancer statistics, 2018;Siegel;Ca - Cancer J Clin,2018

2. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma;Jarnagin;Ann Surg,2001

3. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer;Valle;N Engl J Med,2010

4. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas;Choi;Am J Clin Oncol,2000

5. Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers;Verderame;Ann Oncol,2006

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chinese national clinical practice guideline on diagnosis and treatment of biliary tract cancers;Chinese Medical Journal;2024-09-04

2. Double‐Layered Metal‐Organic‐Frameworks‐Based Microswimmers for Adaptive Dual‐Drug Anti‐Cancer Therapy Using Artemisinin‐Based Compounds;Advanced Intelligent Systems;2024-06-20

3. New clinical trial design in precision medicine: discovery, development and direction;Signal Transduction and Targeted Therapy;2024-03-04

4. Favorable Management of Repeated Serous Retinal Detachment with Continued Tumor Response in a Patient with Intrahepatic Cholangiocarcinoma during Treatment with Pemigatinib;Internal Medicine;2023-04-15

5. Targeted Therapies in Gallbladder Cancer: Current Status and Future Perspectives;Gallbladder Cancer;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3